Q1 2025 OptimizeRx Corp Earnings Call Transcript
Key Points
- OptimizeRx Corp (OPRX) reported Q1 2025 revenues of $21.9 million, an 11% increase year over year, surpassing both consensus estimates and internal expectations.
- The company improved its adjusted EBITDA to $1.5 million, a significant increase from a loss of $0.3 million in Q1 2024.
- Contracted revenue increased by more than 20% year over year, providing strong visibility and positioning for the remainder of the year.
- The company raised its full-year revenue guidance to between $101 million and $106 million, with adjusted EBITDA expected between $13 million and $15 million.
- Early momentum in transitioning to a subscription-based model, with over 5% of projected annual revenue already converted to subscription contracts for 2025.
- Gross margin decreased from 62% in Q1 2024 to 60.9% in Q1 2025, primarily due to product and channel partner mix.
- The company reported a net loss of $2.2 million for Q1 2025, although this was an improvement from a $6.9 million loss in Q1 2024.
- Despite improvements, the company still faces challenges in achieving multi-year subscription contracts due to the annual budgeting nature of the pharma industry.
- The transition to a subscription-based model may impact revenue recognition, spreading revenue over a 12-month period.
- The company has a debt balance of $33.8 million, although it has paid off $6.2 million of principal in Q1 2025.
Good afternoon, everyone. Thank you for joining OptimizeRx first-quarter fiscal 2025 earnings conference call.
With us today is Chief Executive Officer, Steve Silvestro. He is joined by Chief Financial Officer, Ed Stelmakh; Chief Legal Officer, Marion Odence-Ford; and Senior Vice President of Corporate Finance, Andrew D'Silva.
At the conclusion of today's call, I will provide some important cautions regarding the forward-looking statements made by management during today's call.
The company will also be discussing certain non-GAAP financial measures, which it believes are useful in evaluating the company's operating results. A reconciliation of such non-GAAP financial measures is included in the earnings release the company issued this afternoon, as well as in the Investor Relations section of the company's website.
I would like to remind everyone that today's call is being recorded and will be made available for replay, as an audio recording of this conference call, on the Investor Relations section of the company's website.
I would now like to turn the
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
